Health Catalyst Inc Dossier - Source-backed chat

Health Catalyst Inc

HCATNASDAQ

SectorHealth Care

IndustryHealth Care Technology

Beta (adjusted)1.36

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $1.70Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $127.9M

Enterprise Value $220.8M

Shares Outstanding 74.1M diluted

Moat Rating None

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Health Catalyst is undergoing a significant strategic and operational transformation under its newly appointed leadership team (CEO Ben Albert and Chairman Justin Spencer). The company's decision to divest its non-core mid-revenue cycle business, Vitalware, for $147 million in cash is a major positive step that will allow it to fully repay its $160 million senior secured term loan, drastically improving its balance sheet and financial flexibility. Furthermore, the operational restructuring program, Project NEXUS, is expected to deliver $30 million in annualized run-rate cost savings. However, near-term top-line pressure remains evident, with FY2026 revenue guided to decline to $260M–$265M due to migration-related headwinds and professional services reductions. While the valuation is highly compressed (trading at a forward P/S of ~0.4x–0.5x), investors should maintain a Hold stance until there is clear evidence of stabilized organic growth and successful execution of the AI-driven core technology roadmap.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.50

Mean target$1.83

High · most bullish analyst$2.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The Vitalware divestiture faces regulatory delays or execution hurdles, delaying debt repayment and keeping interest expenses high. Client migrations from legacy platforms cause greater-than-expected disruptions, leading to elevated customer churn and revenue falling below the $260 million floor. Additionally, competitive pressures in the healthcare data analytics space limit new bookings, keeping the stock depressed near its historical lows.

Base CaseCentral scenario

The divestiture of Vitalware successfully closes in late 2026, allowing Health Catalyst to eliminate its high-interest debt and achieve a clean balance sheet. Project NEXUS cost-saving initiatives ramp up through the second half of 2026, driving adjusted EBITDA to the guided range of $30M–$33M. Top-line revenue stabilizes within the guided $260M–$265M range, and the newly introduced 'total bookings' metric meets the $22M–$26M target, setting the stage for a modest organic revenue recovery in 2027.

Bull CaseUpside scenario

Health Catalyst's bull case centers on its strategic transformation under 'Project Nexus,' which includes a workforce reduction of approximately 9% to achieve $30 million in annualized run-rate cost savings, and the divestiture of its Vitalware business for $147 million in cash to pay down its senior secured term loan. This pivot shifts focus to its core technology, the AI-driven Ignite platform, and prioritizes profitability and cash flow generation over low-margin services revenue.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strategic divestiture of Vitalware for $147 million cash enables the full repayment of the $160 million senior secured term loan, eliminating substantial debt overhang.
Project NEXUS restructuring is on track to deliver $30 million in annualized run-rate cost savings, significantly improving operating leverage and adjusted EBITDA margins.
Strong cash position of $108.8 million at the end of Q1 2026 (up $13.1 million QoQ) provides a solid liquidity cushion during the transition phase.
Deep foundation of 18 years of proprietary healthcare improvement data and $2.8 billion in documented outcomes serves as a strong competitive moat for its AI roadmap.

Key Investment Risks

Near-term top-line contraction, with FY2026 revenue guided to decline to $260M–$265M from over $300M historically, driven by migration strategies and services reductions.
Execution risk associated with the transition to a new leadership team and the implementation of the Project NEXUS restructuring plan.
Elongated sales cycles and cautious technology spending by healthcare systems due to macroeconomic pressures.
High competition from larger, well-capitalized healthcare technology and consulting vendors.

Thesis Invalidation Triggers

Failure to close the Vitalware divestiture or a material reduction in the transaction value.
FY2026 adjusted EBITDA falling below the guided range of $30 million, indicating failure to capture Project NEXUS cost savings.
Total bookings for FY2026 coming in significantly below the $22 million target, signaling weak market demand for the core platform.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.